Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses
Journal of Veterinary Pharmacology and Therapeutics · 2025-01 · 48 (S1) · 41-49
DOI: 10.1111/jvp.13476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 07.08.2024. Verfasst von Peter Michanek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden. Hauptthemen laut MEDLINE: Canagliflozin, Insulin, Blood Glucose, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish-Norwegian Foundation for Equine Research/Stiftelsen Hästforskning, Stiftelsen Hästforskning.
Abstract (Originalsprache)
Canagliflozin (CFZ) is a sodium‐glucose cotransporter‐2 inhibitor that has shown promising results as a drug for the treatment of insulin dysregulation in horses. Even though CFZ is used clinically, no pharmacokinetic data has previously been published. In this study, the pharmacokinetics of CFZ after administration of a single oral dose of 1.8 mg/kg in eight healthy Icelandic horses was examined. Additionally, the effect of treatment on glucose and insulin levels in response to a graded glucose infusion was investigated. Plasma samples for CFZ quantification were taken at 0, 0.33, 0.66, 1, 1.33, 1.66, 2, 2.33, 2.66, 3, 3.5, 4, 5, 6, 8, 12, 24, 32, and 48 h post administration. CFZ was quantified using UHPLC coupled to tandem quadrupole mass spectrometry (UHPLC‐MS/MS). A non‐compartmental analysis revealed key pharmacokinetic parameters, including a median T max of 7 h, a C max of 2350 ng/mL, and a t 1/2Z of 28.5 h. CFZ treatment reduced glucose (AUC GLU , p = 0.001) and insulin (AUC INS , p = 0.04) response to a graded glucose infusion administered 5 h after treatment. This indicates a rapid onset of action following a single dose in healthy Icelandic horses. No obvious adverse effects related to the treatment were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
- Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences, Oslo, Norway.
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
- Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Peter Michanek, Carl Ekstrand
Förderung
- The Swedish-Norwegian Foundation for Equine Research/Stiftelsen Hästforskning
- Stiftelsen Hästforskning
Zitieren
APA
Michanek, P., Bröjer, J., Lilliehöök, I., Fjordbakk, C. T., Löwgren, M., Hedeland, M., Bergquist, J., & Ekstrand, C. (2025). Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses. Journal of Veterinary Pharmacology and Therapeutics, 48(S1), 41-49. https://doi.org/10.1111/jvp.13476
Vancouver
Michanek P, Bröjer J, Lilliehöök I, Fjordbakk CT, Löwgren M, Hedeland M, et al. Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses. Journal of Veterinary Pharmacology and Therapeutics. 2025;48(S1):41-49. doi:10.1111/jvp.13476
BibTeX
@article{Michanek2025,
author = {Michanek, Peter and Bröjer, Johan and Lilliehöök, Inger and Fjordbakk, Cathrine T and Löwgren, Minerva and Hedeland, Mikael and Bergquist, Jonas and Ekstrand, Carl},
title = {Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2025},
volume = {48},
number = {S1},
pages = {41--49},
doi = {10.1111/jvp.13476}
}
EUVIMED